Yieldstreet is an alternative investments platform that strives to democratize access to financial products historically only available to institutional investors. With Yieldstreet, there are investment opportunities available to both accredited and non-accredited investors looking to invest in funds in the litigation finance, marine finance, and art finance asset classes.
Some tasks are better off automated. Paying bills on time? Automated payments. Orchestrating a coordinated response to security alerts and triaging security events? There’s Splunk Phantom for that. Monotonous tasks, in our work and personal lives, should and can be automated in order to free up time and energy to focus on the things that matter.
SimpleHealth takes their company name to heart. They are a reproductive tele-health company, focused on building thoughtful and impactful services that enable patients to own their reproductive health journey. Today, the core vertical is an online birth control prescription and free home delivery service.
Having closed brick-and-mortar operations on March 16, 2020 for safety reasons, the nearly overnight shift to a purely e-commerce revenue model brought uncertainty. However, a rapid uptick in online sales provided a sense of relief, albeit short-lived. Our client became concerned when a closer look at the online transactions revealed an unusually large volume of electronic gift card purchases made using their private label credit card.
Credit card attacks typically target point of sale (PoS) terminals at retail locations such as stores, restaurants and hotels. In the early stages of the COVID-19 pandemic, in-person retail activity greatly diminished, forcing criminals to seek other targets and to virtualize their operations.
Before selecting Veracode, Advantasure, a leader in the healthcare technology industry, was on the hunt for an AppSec program that would not only protect them against cyberattacks, but also prove compliance with laws and regulations in several states.
Chris Moxham, Ph.D., is the Chief Scientific Officer at Fulcrum Therapeutics, an innovative biotech addressing the causes of genetically defined disease. By developing treatments that address the root cause of disease, Fulcrum goes a step further than creating therapies that just manage symptoms and develops treatments that alter the genetic expression of disease, enabling life-changing outcomes.
